{"id":461527,"date":"2026-03-03T23:03:16","date_gmt":"2026-03-03T22:03:16","guid":{"rendered":"https:\/\/medizinonline.com\/utilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra\/"},"modified":"2026-01-28T14:18:01","modified_gmt":"2026-01-28T13:18:01","slug":"utilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/utilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra\/","title":{"rendered":"Utilizaci\u00f3n de los efectos pleiotr\u00f3picos cardioprotectores y nefroprotectores de SGLT-2-i y GLP-1-RA"},"content":{"rendered":"\n<p><strong>Seg\u00fan los conocimientos actuales, la diabetes de tipo 2 es una enfermedad multisist\u00e9mica, en cuyo pron\u00f3stico influye significativamente la patolog\u00eda cardiaca y renal. Por lo tanto, es importante un enfoque terap\u00e9utico precoz y multimodal que vaya m\u00e1s all\u00e1 del mero control de la glucemia. En la actualidad existen pruebas emp\u00edricas de que los inhibidores de SGLT-2 y los agonistas del receptor de GLP-1 ofrecen beneficios cardioprotectores y nefroprotectores, y estudios recientes han demostrado que pueden conseguirse efectos sin\u00e9rgicos mediante su uso combinado.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Futilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Seg\u00fan los conocimientos actuales, la diabetes de tipo 2 es una enfermedad multisist\u00e9mica, en cuyo pron\u00f3stico influye significativamente la patolog\u00eda cardiaca y renal. Por lo tanto, es importante un enfoque&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Futilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":461528,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Diabetes de tipo 2: control gluc\u00e9mico y prevenci\u00f3n de enfermedades secundarias","footnotes":""},"category":[11324,11483,11352,11475,11377,11552],"tags":[88266,15933,12033,65639,88265,18648],"powerkit_post_featured":[],"class_list":["post-461527","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologia","category-el-congreso-informa","category-endocrinologia-y-diabetologia","category-estudios","category-nefrologia","category-rx-es","tag-consecuencias-enfermedades-cardioprotectoras","tag-control-glucemico","tag-diabetes-tipo-2-es-2","tag-glp-1-ra-es-2","tag-nefroprotector-2","tag-sglt-2-i-es","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-01 21:56:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/461527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=461527"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/461527\/revisions"}],"predecessor-version":[{"id":461529,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/461527\/revisions\/461529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/461528"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=461527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=461527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=461527"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=461527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}